SEPN - NASDAQ

Septerna, Inc.

SEPN·NASDAQ

$30.55

+2.0%

HealthcareBiotechnology

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.38B

EPS-1.1000

P/E Ratio-27.77

Earnings Date08/10/2026

596.19M

Assets

31%

3Y+1551.0%

5Y+1551.0%

10Y+1551.0%

214.26M

Total Liabilities

487%

3Y+167.0%

5Y+167.0%

10Y+167.0%

381.93M

Total Equity

-9%

3Y-964.0%

5Y-964.0%

10Y-964.0%

Septerna, Inc. Funding & Solvency Profile

SEPN · NASDAQ

Current Assets

Cash & Cash Equivalents120.72M

Net Receivables10.36M

Inventory0.00

Other Current Assets9.52M

Total Current Assets411 M

Non-Current Assets

Property, Plant & Equipment25.93M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets159.29M

Total Non-Current Assets185 M

Total Assets

596.19M

Financial Health Analysis

Current Ratio

4.73x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.56x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

324 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

69% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Septerna, Inc. Balance Sheet

SEPN • NASDAQ

Septerna, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	120.7M	238.2M	88.5M	30.6M
Short-Term Investments	270.4M	112.7M	0.0	0.0
Cash & Short-Term Investments	391.1M	350.9M	88.5M	30.6M
Net Receivables	10.4M	1.1M	22.8M	0.0
Accounts Receivables	10.4M	171K	151K	0.0
Other Receivables	0.0	953K	22.6M	0.0
Prepaids	0.0	4.6M	1.3M	1.1M
Other Current Assets	9.5M	200K	92K	204K
Total Current Assets	411M	356.8M	112.7M	31.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	25.9M	28.7M	17.2M	3.1M
Long-Term Investments	0.0	69.9M	0.0	0.0
Other Non-Current Assets	159.3M	1.2M	1M	1.1M
Total Non-Current Assets	185.2M	99.7M	18.2M	4.2M
Total Assets	596.2M	456.6M	130.9M	36.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10.3M	3.2M	2.8M	3.1M
Accounts Payable	10.3M	3.2M	2.6M	3.1M
Other Payables	0.0	0.0	200K	0.0
Accrued Expenses	0.0	3.6M	1M	6K
Short Term Debt	2.2M	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.9M	0.0	710K
Tax Payables	0.0	0.0	200K	0.0
Deferred Revenue	62.3M	0.0	0.0	0.0
Other Current Liabilities	12.2M	4.2M	3M	1.8M
Total Current Liabilities	86.9M	12.8M	6.9M	5.5M
NON-CURRENT LIABILITIES
Long Term Debt	21.4M	0.0	0.0	0.0
Other Non-Current Liabilities	105.9M	33K	149.8M	74.8M
Total Non-Current Liabilities	127.3M	23.7M	162.3M	74.8M
Capital Lease Obligations	0.0	25.5M	12.6M	710K
Total Liabilities	214.3M	36.5M	169.2M	80.3M
SHAREHOLDERS' EQUITY
Common Stock	45K	44K	3K	3K
Additional Paid-In Capital	548.5M	538.3M	8.2M	6.6M
Retained Earnings	-167.3M	-118.4M	-46.6M	-50.8M
Accumulated Other Comprehensive Income/Loss	617K	56K	0.0	0.0
Total Stockholders' Equity	381.9M	420M	-38.4M	-44.2M
Total Equity	381.9M	420M	-38.4M	-44.2M
SUMMARY
Total Liabilities & Equity	596.2M	456.6M	130.9M	36.1M
Total Investments	270.4M	182.6M	0.0	0.0
Total Debt	23.6M	25.5M	12.6M	710K
Net Debt	-97.1M	-212.7M	-75.9M	-29.9M
Shares Outstanding	44,585,135	44,585,135	44,585,135	44,585,135

SEC Filings

SEPN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 09, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 10, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 35 filings

Related Guides

Blog Categories

Continue your SEPN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.